Table 1.
Main features of the cohorts analyzed in this study.
| GEICAM/9906 | SOLTI-Neoeribulin | PETx | GEICAM/2009-03 | GEICAM/2012-09 | HCB | IBIMA | CBM | |
|---|---|---|---|---|---|---|---|---|
| Dataset | Training | Training | Training | Training | Training | Testing | Testing | Testing |
| N | 531 | 93 | 56 | 50 | 173 | 194 | 176 | 144 |
| IHC | Centralized | Local | Local | Centralized | Centralized | Centralized | Centralized | Centralized |
| Platform | qRT-PCR | nCounter | nCounter | nCounter | nCounter | nCounter | nCounter | nCounter |
| PAM50 non-luminal disease (%) | 77 (14.5) | 12 (12.9) | 3 (5.3) | 7(14) | 5 (2.9) | 7 (3.6) | 21 (11.9) | 5 (3.5) |
| HER2-E (%) | 71 (13.4) | 1 (1.1) | 3 (5.3) | 6 (12) | 4 (2.3) | 4 (2.1) | 7 (4.0) | 3 (2.1) |
| Basal-like (%) | 6 (1.3) | 11 (11.8) | 0 | 1 (2) | 1 (0.6) | 3 (1.5) | 14 (7.9 | 2 (1.4) |